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INTRODUCTION:- 
Majority of drugs are frequently administered through oral 
route, but approximately 40% of new drug candidates have 
poor‐water solubility and the oral delivery of such drugs is 
complicated for the reason that of their low bioavailability, 
high intra‐ and inter‐subject variability, and not have dose 
linearity
1,2
. To overcome these problems, a variety of 
strategies have been developed including the use of 
surfactants
3
, lipids
4
, permeation enhancers
4
, 
micronization
5
, salt formation
6
, cyclodextrins
7
, 
nanoparticles and solid dispersions
4,5 
etc. There has been 
emergent attention in the use of lipid excipients in self‐
emulsifying lipid formulations (SELFs) for the reason that 
of their capability to solubilize poorly water‐soluble 
'lipophilic' drugs and prevail over the problem of poor drug 
absorption and bioavailability
8
.  
 Micro emulsions and self-emulsifying systems have 
emerged as potential solubility enhancing technologies, 
whose solubilising and absorption promoting effect is 
thought to lay in the reactivity of triglycerides and 
surfactants with the walls of the gastrointestinal tract. 
Traditionally, long and medium-chain triglycerides (LCTs 
and MCTs, respectively) have been employed with 
surfactants to incorporate drugs into self- emulsifying 
systems
8
. Non-ionic surfactants, such as Tweens 
(polysorbates) and labrafil (poly-oxy-ethylated oleic 
glycerides), with high hydrophile-lipophile balances 
(HLB) are often used to ensure immediate formation of 
oil-in-water (o/w) droplets during production
9
.  
 Amphiphilic, non-ionic surfactants allow higher degrees 
of drug solubilisation to occur and may prevent the 
precipitation of drug out of the micro-emulsion in vivo. 
Co-surfactants are frequently employed to increase the 
amount of drug capable of being dissolved into the lipid 
base, because the concentration of surfactant in most self-
emulsifying systems is required to be in excess of 30 per 
cent w/w. These co-surfactants are often organic solvents 
suitable for oral administration, such as ethanol, propylene 
glycol and poly ethylene glycol
10
. Most self-emulsifying 
systems are limited to administration in lipid-filled soft or 
hard-shelled gelatin capsules due to the liquid nature of the 
product. Interaction between the capsule shell and the 
emulsion should be considered so as to prevent the 
hydroscopic contents from dehydrating or migrating into 
the capsule shell
11
. 
Atorvastatin, as a synthetic lipid-lowering agent, is an 
inhibitor of 3-hydroxy-3-methyl- glutaryl-coenzyme A 
(HMG CoA) reductase which catalyzes the conversion of 
HMG-Co A to mevalonate, an early rate-limiting step in 
cholesterol biosynthesis. Atorvastatin is currently used as 
calcium salt for the treatment of hypercholesterolemia. It is 
insoluble in aqueous solution of pH 4 and below; it is very 
slightly soluble in water and pH 7.4 phosphate buffer. The 
intestinal permeability of atorvastatin is high at the 
physiologically relevant intestinal pH. However, it is 
reported that the absolute bioavailability (F) of atorvastatin 
is 12% after a 40 mg oral dose
12
. In present study 
SMEDDS of Atorvastatin was prepared for enhanced 
solubility and dissolution of poorly soluble drug. 
MATERIALS AND METHODS:  
Atorvastatin calcium (API), soybean oil, sunflower oil and 
olive oil obtained as a gift sample from Bright Labs, 
Hyderabad. Brij 30, Acetonitrile (HPLC grade), potassium 
dihydrogen phosphate, Ortho phosphoric acid (AR grade) 
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were procured from Qualigens Ltd., Mumbai. Tween 80, 
oleic acid, PEG 400, methanol (AR grade) were procured 
from S.D Fine chemicals, Mumbai. HPLC grade water was 
obtained from SD-Lab star (3TWF-UV) water purification 
system. 
Solubility Studies:  
To quantify and understand the solubility studies 
of atorvastatin an analytical method using RP-HPLC 
(Shimadzu Prominence LC-20AD was developed, 
optimized and validated. The solubility of atorvastatin 
calcium in various oils (soybean, sunflower & olive), 
surfactant and co-surfactants was measured using vial 
shake method. Unknown amount of selected vehicles was 
added to each cap vial containing an excess of atorvastatin 
, heated up to 40
o
C and centrifuged (Remi RM-12C 
centrifuge) at 3000 rpm for 5 min. Excess insoluble 
atorvastatin was discarded by filtration using a membrane 
filter (0.45 μm, 13 mm). The concentration of atorvastatin 
was then quantified by RP-HPLC method (Shimadzu 
Prominence LC-20AD). Solubility study was performed at 
triplicate and standard deviation was calculated.  
Preliminary screening of surfactants:- 
  Different surfactants for the per oral use were 
screened for emulsification ability. Briefly, 150 mg of each 
surfactant was added to 150 mg of the oily phase, heated 
up to 50
0
C and diluted to 100 ml with water. Ease of 
emulsification was judged by the number of flask 
inversions required to yield homogenous emulsion. 
Emulsions were allowed to stand for 2 hours and their 
percentage transmittance was evaluated by UV-Visible 
spectrophotometer
13
 (Shimadzu, Japan). Emulsions were 
furthermore observed visually for any turbidity or phase 
separation. The selected oily phase and surfactant were 
used for further screening of the different co-surfactants 
(Brij 30 and tween 80) for their emulsification ability.  
Construction of Ternary phase diagram:
 
 The ability of oil within surfactant: co-surfactant 
that could self-emulsify under proper dilution can be 
identified and selected from ternary phase diagrams. 
Ternary phase diagram were constructed using water 
titration method. The mixture of oil with surfactant or 
combination of surfactant and co-surfactant were prepared 
in different ratios, titrated against water and agitated (Remi 
CM 101 DX) until slightly bluish emulsion was formed. 
Percentage of oil, surfactant: co-surfactant mixture and 
water was calculated using ternary phase diagram. 
CHEMEX 3.51 software tool was used to find out the 
emulsification zone
14
. Further the same procedure was 
repeated instead of oil surfactant mix to determine the 
effect of drug on phase diagram. 
Formulation of SNEDDS:
 
10 mg of atorvastatin was dissolved in co-
surfactant at 45˚C in an isothermal water bath. After 
cooling, calculated amount oil and surfactant was added 
and sonicated (Citizen Digital, India) until a clear solution 
was obtained. The formulation was equilibrated at ambient 
temperature for at least 48 hours to examine the signs of 
turbidity or phase separation. Formulations made were 
examined for leakage by filling in hard gelatin capsules
15
. 
Table1. Various Formulations using oil: co-surfactant/surfactant ratio 
Formulation code Drug (mg) % Oleic acid % Tween 80 % Brij 30 
BF1 10 5 47.5 47.5 
BF2 10 5 63.33 31.66 
BF3 10 10 45 45 
BF4 10 10 60 30 
BF5 10 15 42.5 42.5 
BF6 10 20 56.66 28.33 
BF7 10 20 40 40 
BF8 10 25 53.33 26.66 
BF9 10 25 37.5 37.5 
BF10 10 25 50 25 
BF11 10 30 35 35 
BF12 10 30 46.66 46.66 
BF13 10 35 32.5 32.5 
BF14 10 35 43.33 21.66 
BF15 10 40 30 30 
BF16 10 40 40 20 
BF17 10 45 27.5 27.5 
BF18 10 45 36.66 18.33 
BF19 10 50 25 25 
BF20 10 50 33.33 16.66 
 
Characterization: 
1. Determination of self -emulsification time:
 
The primary means of self-emulsification 
assessment is by visual evaluation. The efficiency of self-
nano-emulsification is estimated by agitation at 100 rpm in 
mixture of water and 0.1N HCl solution (100ml) at 
temperature 37ºC
15
. The time required to form nano-
emulsion depends upon dilution of SNEDDS with water. 
2. Visual observation, Phase separation and stability 
study of emulsion: 
Different formulations were diluted, agitated with 
20ml of distilled water at 37˚C and allowed to stand for 24 
hours. Further visual observation was made to check the 
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extent of phase separation and precipitation. Mixtures 
exhibiting a negligible phase separation during the 24 hour 
period were selected for further studies and evaluated on 
visibility grades
16
. 
Table- 2 Visibility grades 
Grade Dispersibility and appearances 
I Clear or slightly bluish in appearance 
II Bluish white appearance. 
III Bright white emulsion (similar to milk 
IV Dull, grayish white emulsion with a slightly oily appearance 
V Turbid appearance 
 
 
  
3. Droplet size, Zeta potential and poly-dispersity 
analysis: 
The mean droplet size, zeta potential and poly-
dispersity index of formulations was determined by using 
Zeta seizer HAS 3000 (Malvern Instruments Ltd., Malvern, 
UK). Light scattering was monitored at 25
o
C at a 90
o
 
angle
16
. The dispersed formulations were measured after 
dilutions (1:100). 
4. FTIR studies: 
Infrared (IR) spectroscopy studies were 
conducted using FTIR (Bruker Alpha T, Germany) at 4000 
to 500 cm
-1
. Liquid sample preparations were made as per 
the instrument and the spectrum was recorded for various 
formulations
17
. 
5. Physical analysis: 
The surface morphology, roundness, formation of 
aggregates and size distribution of nano globules formed 
were studied by Scanning Electron Microscopy (Model: 
JSM-5510Jeol Ltd, Tokyo, Japan). 1gm of formulation 
was diluted with 10ml of pH 6.8 phosphate buffer. The 
nano-emulsions were mounted on an aluminum stub using 
double-sided carbon adhesive tape. Then the vesicles were 
sputter-coated with gold palladium (Au/Pd) using a 
vacuum evaporator and examined with digital camera, at 
20kV accelerating voltage
17
. 
6. Drug content:  
Various formulations equivalent to 10 mg were 
taken into a standard volumetric flask, mixed and diluted 
with methanol. 1 ml of this solution was diluted to 10 ml 
with phosphate buffer pH 6.8; it gives 100µg/ml 
(theoretical). Further drug content was quantified using 
RP-HPLC method developed at 246 nm.  
 
 
 
 
 
7. Cloud point measurement:
 
Formulations were diluted with 50 ml of water 
and placed on a water bath with gradually increase the 
temperature until the diluted formulation turned to cloudy. 
It gives the information about the stability of the nano-
emulsion at body temperature
18
.
 
8. In vitro release study:
 
Quantitative in vitro release test was performed 
using USP XXIV method (dissolution apparatus #2, at 50 
rpm) in 900 ml 0.05M phosphate buffer at pH 6.8. 
SNEDDS (equivalent to 10 mg) was placed in dialysis bag 
to compare the release profile with conventional tablets
19
. 
10 ml of sample solution was withdrawn at predetermined 
time intervals, filtered through a 0.45 μm membrane filter, 
dilute suitably and analyzed chromatographically (RP-
HPLC). Equal amount of fresh dissolution medium was 
replaced immediately after withdrawal of the test sample. 
Percentage cumulative drug released at different time 
intervals was calculated and graph plotted versus time. 
9. In vitro rat intestinal permeability study:
 
Various methods employed for intestinal 
permeability were modified within experimental 
procedures described in the literature. Male albino rats 
(250-300 grams) were killed by overdose with 
pentobarbitone IV injection. To check the intra-ileum 
permeability, the ileum part of intestine was isolated, 
washed thoroughly with cold Ringer’s solution to remove 
the mucous and lumen contents. The formulations were 
diluted with 1 ml of distilled water and sample (1 mg/mL) 
was injected into the ileum using a syringe, making sure 
two sides of the intestine are tightly closed. The tissue was 
placed in a chamber of organ bath with continuous aeration 
at 37ºC. The receiver compartment was filled with 30 ml 
of 0.05M phosphate-buffered saline (pH 6.8). At 
predetermined time intervals of 15, 45, 75,105,135 and 
165 minutes (up to 2.75 hours), 2 ml of the samples were 
withdrawn and the drug concentration was determined by 
validated HPLC method
20
.  Percentage cumulative drug 
absorption of drug was calculated by plotting the graph 
versus time. The same procedure was repeated for 
marketed tablet.  
10. Thermodynamic Stability Studies:  
1. Freeze–thaw cycle:  
Freeze thawing was employed to evaluate the 
stability of formulations. The formulations were subjected 
to 3 to 4 freeze-thaw cycles, which included freezing at – 
4°C for 48 hours followed by thawing at 40°C for 48 
hours. Centrifugation was performed at 3000 rpm for 5 
minutes
21
. The formulations were then observed for phase 
separation. Only formulations that were stable to phase 
separation were selected for further studies. 
% of drug = 
𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 
𝑠𝑎𝑚𝑝𝑙𝑒 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎
×100 
Standard peak area at 100µg/ml 
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2. Stability Studies: 
The hard gelatin capsules (size 0) filled with 
different formulation was placed in stability chambers 
(REMI, India). Stability studies at 25°C/ 60% RH, 
30°C/65% RH, and 40°C/75% RH were conducted 
according to ICH guidelines. Sampling was done at 
specified intervals over a period of 3 months for 
intermediate and accelerated conditions and 6 months for 
long-term conditions
21
. Drug content of the capsules was 
analyzed using developed RP-HPLC method. 
RESULTS AND DISCUSSION:  
Solubility studies:  
Table 3 Solubility of Atorvastatin in various oils, 
surfactants and co-surfactants 
 
 
 
Selection of right component is important prerequisite for 
formulation of stable SNEDDS. The drug should have 
good solubility in components of micro emulsion so as the 
precipitation of drug during shelf life of formulation and 
after dilution in GI lumen can be avoided. Therefore, the 
solubility of atorvastatin calcium was determined in 
various oils, surfactants and co-surfactant mixtures. The 
solubility results are depicted in figure I. Among the 
various components studied oleic acid, Brij 30 and Tween 
80 showed maximum solubility 9.8 ± 1.79, 73.87 ± 1.73 
and 54.83 ± 0.51 mg/ml respectively. The solubility results 
for oil: surfactant mixtures are showed in Table 3. 
 
As the solubility of atorvastatin was maximum in oleic 
acid, Brij 30 and Tween 80 these were selected as oil and 
surfactant component for further development of 
SNEDDS. Final selection among different components 
would secondly be confirmed according to emulsification 
properties with other ingredients. Regarding surfactants 
and co-surfactants selection, drug solubility would come 
second to the main selection perspective: emulsification 
efficiency. 
Tween 80 a non-ionic surfactant with high HLB value 15, 
which has miscible with atorvastatin, being less toxic and 
less affected by pH and ionic changes in the dispersion 
medium. Oleic acid was selected as oily phase because it 
has ability of high spontaneity for emulsification and high 
drug loading capacity. Brij 30 (HLB-9) was selected as co-
surfactant it is a medium chain mono glyceride promotes 
water penetration and has good solvent capacity for drugs. 
 
Figure-1 Solubility of atorvastatin in various oils, surfactants and co-surfactants 
 
 
 
Phase diagram 
Figure 2 and 3 represents the phase diagrams of 
oil-surfactant-water systems:  (oleic acid, Tween 20: Brij 
30 and water) in different ratios. These phase diagrams 
showed the different areas of bluish nano emulsion (NE), 
slightly bluish micro emulsion (ME), and coarse emulsions 
(ME). It can be seen that the largest micro emulsion region 
0
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SNO Vehicle Solubility in mg/ml 
1 Miglyol 0.33 
2 Oleic acid 9.4 
3 Iso propyl myristate 0.73 
4 Cotton seed oil olive oil 8.36 
5 Olive oil 7.21 
6 Soya oil 4.89 
7 Tween 80 73.87 
8 Tween 20 37.14 
9 Span 80 69.5 
10 Span 20 26.5 
11 Cremophore RH 40 32.4 
12 PEG 400 93.3 
13 Brij 30 54.8 
14 Transcutol-p 48.9 
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is seen when the combination of surfactant and co-
surfactant are used.  
Ternary phase diagrams were constructed to identify the 
self-emulsifying regions and also to establish the optimum 
concentrations of oil, surfactant and co-surfactant. From 
the phase diagrams, it was observed that as increasing the 
concentration of surfactant increased the self-emulsifying 
region. Emulsification region decreased with increasing 
the concentration of co-surfactant. Efficiency of self-
emulsification was good when the surfactant concentration 
was more than 50%. From the formulations as the 
concentrations of oil increases (above 35%) showed the 
phase separation of SNEDDS formulation. Effect of drug 
on phase diagram study was conducted to check the effect 
of emulsification region and stability of the emulsification 
process. Emulsification zone was narrowed as the 
concentration of drug increased, viscosity of the system is 
increased and some formulations showed gel like 
appearance. BF8, BF10 showed increase in the viscosity. 
BF16, BF18 and BF20 very viscous emulsions because the 
concentration of oil and surfactant concentration increases 
the viscosity y of the system increased, transparent 
emulsion was formed with increase in the concentration of 
concentration of Brij 30. 
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                         Figure 2- 2:1 ratio                                                     Figure 3- 1:2 ratio 
Characterization: 
1. Visible Assessment, Phase separation and Stability 
study: 
Formulations BF1 to BF11 showed no crystal growth 
or no precipitation which formed micro emulsion upon 
dilution and was stable for 24 hours. The remaining 
formulations showed phase separation and precipitation. It 
indicates that as concentration of oil increases the stability 
of formulation is decreased and also increase in surfactant 
content the clarity is better.  
Table 4. Visible assessment SNEDDS after dilution and phase separation, precipitation results on storage 
Formulation code Visibility grade Phase separation Precipitation 
BF1 II X XX 
BF2 I X XX 
BF3 II X XX 
BF4 I X XX 
BF5 II X XX 
BF6 II X XX 
BF7 II X XX 
BF8 II X XX 
BF9 III X XX 
BF10 IV X XX 
BF11 III X XX 
BF12 IV + XX 
BF13 V + ++ 
BF14 V + ++ 
BF15 V + ++ 
BF16 V + ++ 
BF17 V + ++ 
BF18 V + ++ 
BF19 V + ++ 
BF20 V + ++ 
         X-- No phase separation, XX--No precipitation, +--phase separation and ++--precipitation. 
Mallesh et al                               Journal of Drug Delivery & Therapeutics; 2013, 3(3), 131-142    136 
2011, JDDT. All Rights Reserved                                                        ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
2. Determination of Emulsification Time: 
In the study formulations (BF1-BF11) have shown spontaneity of emulsification and good stability without any signs 
of drug or excipient precipitation. 
Table 5. Emulsification times of various SNEDDS formulations in 0.1N HCl and distilled water. 
Formulation 
code 
0.1N HCl Distill water 
Emulsification time 
(sec) 
Tendency for 
emulsification 
Emulsification time 
(sec) 
Tendency for 
emulsification 
BF1 67 good 73 good 
BF2 56 good 61 good 
BF3 82 good 92 good 
BF4 71 good 84 good 
BF5 87 good 98 good 
BF6 76 good 85 good 
BF7 96 good 112 bad 
BF8 83 good 91 good 
BF9 119 good 127 bad 
BF10 128 good 142 bad 
BF11 132 good 156 bad 
 
         Figure -2 Emulsification times of various formulations in 0.1N HCl & distilled water 
        
3. Droplet size measurements: 
From the results, as the concentration of brij 30 increases uniformity of the nano emulsion decreased. Further 
characterizations were carried with formulations BF1, BF2, BF4 and BF6. 
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Table 6. Droplet size, PDI of the SNEDDS formulations 
Formulation code Droplet size (nm) Poly Dispersity Index 
BF1 198 0.282 
BF2 155.1 0.179 
BF3 217 0.412 
BF4 162.2 0.297 
BF5 226 0.415 
BF6 178.5 0.315 
BF7 242 0.556 
BF8 236.5 0.489 
 
Figure 3. Droplet size of nano emulsion 
                     
 
4. Zeta potential measurement: 
Zeta potential of all SNEDDS formulation was in 
range of –17 to –30 mV in the 50 times dilution. SNEDDS 
formulations consist of non-ionic components and oleic 
acid which show relatively negative charge. Formulations 
BF4 and BF6 have surface charge more than 25mv 
meaning will not be affected by cell membrane charge 
during absorption and also can produce stable nano 
emulsion particles. The results were similar of phenytoin. 
Table 7. Zeta potential of formulations 
 
 
 
 
 
4. Cloud point measurement: 
Cloud points of all formulations were very high 
about 80˚C. In all formulations, cloudiness was reversible 
after few minutes. Phase separation, 
precipitation occurred possible due to dehydration of POE 
moiety, alkyl chains of surfactant system
. 
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Formulation code Zeta potential (mv)  
BF1 -16±4.35 
BF2 -18±5.65 
BF4 -24.6±6.47 
BF6 -28±5.84 
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Table 8. Cloud point of stable SNEDDS formulation 
Formulation code Cloud point 
BF1 74±6.52 
BF2 73±5.15 
BF4 80±4.64 
BF6 76±5.8 
 
5. Thermodynamic stability study: 
Thermodynamic stability study was designed to 
identify and avoid the metastable formulations.  
The formulations were stable during centrifugation at 3500 
rpm at alternative temperature cycles of 40˚c and -4˚c. 
There was no phase separation and precipitation observed.  
6. FTIR Studies: 
From the spectra, it is observed there is possibility 
of intermolecular hydrogen bonding between adjunct 
atorvastatin molecules. The spectrum of pure atorvastatin 
was equivalent to the spectra obtained by the SNEDDS 
indicating there were no possible incompatibilities. 
Figure 4 IR spectra of pure atorvastatin 
              
 
 
 
 
 
 
 
 
                      Figure 5 Comparison of IR spectra of atorvastatin with SNEED formulation 
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7. Physical Analysis of globules:  
Scanning electron micrographs revealed the formation of well identified spherical globules with sharp boundaries 
after hydration, similar to those seen with lutein loaded novel SNEDDS. The surface characteristics of SNEDDS-derived 
nano emulsion are depicted in the figure 6.     
Figure 6     (a) SEM at 1μm                                                            (b) SEM at 200nm 
 
 
 
 
 
 
 
 
 
 
 
 
8. Drug content: 
The drug content for the selected formulation was calculated using the standard formula. 
Table 9 Percentage of drug in various formulations 
Formulation code Percentage of drug 
BF1 99.52 
BF2 98.42 
BF4 99.67 
BF6 99.33 
 
9. In-vitro release studies: 
The percent cumulative release of Atorvastatin 
from the formulations BF4 and BF6 was found to be 
higher than the other formulations and marketed product 
(storvas
® 
10 mg). The percentage drug released after 90 
minutes for BF4 and BF6 were 99.65% and 89.26% were 
as 56.86% release for marketed product. Cumulative 
percent drug release is high in formulation BF4 because of 
low viscosity and high concentration of surfactant i.e. 
Tween 80. 
Table 10. Cumulative percent release of Atorvastatin from various formulations 
Time(min) BF1 BF2 BF4 BF6 
crude  
drug 
marketed 
product 
0 0 0 0 0 0 0 
5 24.24 26.28 39.12 32.46 8 16 
10 36.33 33.59 58.34 49.56 10.5 22.64 
20 41.54 42.56 71.65 68.67 12.88 26 
30 44.21 51.62 78.66 74.65 15.3 34.99 
40 49.63 56.31 86.89 79.98 16.98 41.24 
50 54.21 59.35 91.26 82.78 18.56 46.66 
60 58.66 63.3 94.12 85.55 21.36 48.54 
75 62.43 69.5 97.66 87.33 23.55 52.64 
90 64.99 73.6 99.65 89.26 25.86 56.86 
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Figure 7 Percentage cumulative drug release of various formulations. 
               
10. In vitro rat intestinal permeability study: 
From the results it was observed that formulation BF4 has shown highest oral absorption (86.67%) thorough 
intestine after 165 seconds when compared to marketed product (45.34%). This may suggest absorption of the drug 
through the intestine increases with decreasing droplet size. 
Table11 Percent cumulative drug absorbed through the rat skin 
Time (min) BF4 Marketed product 
0 0 0 
15 24.35 15.25 
45 42.35 21.99 
75 59.33 32.68 
105 72.69 39.98 
135 81.31 41.45 
165 86.67 45.34 
 
                 Figure 8 Comparison of intestinal absorption between BF4 and marketed product 
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11. Stability studies: 
The formulations BF4 and BF6 were found to be stable for 3 months and there was no significant change in the drug 
content, or particle size. 
Table 12. Evaluation data of SNEDDS formulation subjected to stability studies at (25
o
c/60% RH) 
Formulation code 
Sampling point 
 
Droplet size size(nm) % drug content 
 
BF6 
0 days 
45 days 
3 months 
178.5 
178.5 
179.5 
99.33 
98.75 
97.98 
 
BF4 
0 days 
45 days 
3 months 
162.2 
162 
165 
99.67 
98.28 
97.51 
 
                 Figure 9 Droplet sizes of the formulations after 3 months at 25
o
c/60% RH. 
                               
                                 Figure 10 Drug content after storage at 25
o
c/60% RH 
 
CONCLUSION: 
An optimized atorvastatin loaded formulation consisting of 
oleic acid, Tween 80 and Brij 30 offers the advantage of 
good solubilisation of atorvastatin. Thus our studies 
confirmed that SNEDDS can be used as a possible 
alternative to conventional oral formulation of atorvastatin. 
Results further conclude that SNEDDS can be explored as 
a potential drug carrier for dissolution enhancement of 
atorvastatin and other insoluble drugs. 
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